Peer reviewed
Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6)
Pre-specified CV outcomes trial establishing cardiovascular safety of semaglutide in Type 2 diabetes.
New England Journal of MedicinePublished Nov 10, 2016Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-semaglutide-sustain6-2016
Source usage
Linked from 3 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.